Results from PREVANZ, a phase 2b placebo controlled double blind dose ranging study of vitamin D to prevent progression to definite multiple sclerosis after a high risk clinically isolated syndrome

H. Butzkueven; A-L Ponsonby; M. Stein; R. Lucas; D. Mason; S. Broadley; T. Kilpatrick; J. Lechner-Scott; M. Barnett; W. Carroll; J. Andrew; H. Campbell; J. Morahan; K. Dear; B. Taylor

Results from PREVANZ, a phase 2b placebo controlled double blind dose ranging study of vitamin D to prevent progression to definite multiple sclerosis after a high risk clinically isolated syndrome

H. Butzkueven, A-L Ponsonby, M. Stein, R. Lucas, D. Mason, S. Broadley, T. Kilpatrick, J. Lechner-Scott, M. Barnett, W. Carroll, J. Andrew, H. Campbell, J. Morahan, K. Dear, B. Taylor

Centre for Neuromuscular and Neurological Disorders (Perron Institute)

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

Original language	English
Pages (from-to)	978-979
Number of pages	2
Journal	Multiple Sclerosis Journal
Volume	28
Issue number	3_SUPPL
Publication status	Published - Oct 2022
Event	38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis - Amsterdam, Netherlands Duration: 26 Oct 2022 → 28 Oct 2022

Cite this

Butzkueven, H., Ponsonby, A.-L., Stein, M., Lucas, R., Mason, D., Broadley, S., Kilpatrick, T., Lechner-Scott, J., Barnett, M., Carroll, W., Andrew, J., Campbell, H., Morahan, J., Dear, K., & Taylor, B. (2022). Results from PREVANZ, a phase 2b placebo controlled double blind dose ranging study of vitamin D to prevent progression to definite multiple sclerosis after a high risk clinically isolated syndrome. Multiple Sclerosis Journal, 28(3_SUPPL), 978-979.

@article{7d9d48a09ff4444680dc35ee5405d446,

title = "Results from PREVANZ, a phase 2b placebo controlled double blind dose ranging study of vitamin D to prevent progression to definite multiple sclerosis after a high risk clinically isolated syndrome",

author = "H. Butzkueven and A-L Ponsonby and M. Stein and R. Lucas and D. Mason and S. Broadley and T. Kilpatrick and J. Lechner-Scott and M. Barnett and W. Carroll and J. Andrew and H. Campbell and J. Morahan and K. Dear and B. Taylor",

year = "2022",

month = oct,

language = "English",

volume = "28",

pages = "978--979",

journal = "Multiple Sclerosis Journal",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "3_SUPPL",

note = "38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis ; Conference date: 26-10-2022 Through 28-10-2022",

}

Butzkueven, H, Ponsonby, A-L, Stein, M, Lucas, R, Mason, D, Broadley, S, Kilpatrick, T, Lechner-Scott, J, Barnett, M, Carroll, W, Andrew, J, Campbell, H, Morahan, J, Dear, K & Taylor, B 2022, 'Results from PREVANZ, a phase 2b placebo controlled double blind dose ranging study of vitamin D to prevent progression to definite multiple sclerosis after a high risk clinically isolated syndrome', Multiple Sclerosis Journal, vol. 28, no. 3_SUPPL, pp. 978-979.

Results from PREVANZ, a phase 2b placebo controlled double blind dose ranging study of vitamin D to prevent progression to definite multiple sclerosis after a high risk clinically isolated syndrome. / Butzkueven, H.; Ponsonby, A-L; Stein, M. et al.
In: Multiple Sclerosis Journal, Vol. 28, No. 3_SUPPL, 10.2022, p. 978-979.

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

TY - JOUR

T1 - Results from PREVANZ, a phase 2b placebo controlled double blind dose ranging study of vitamin D to prevent progression to definite multiple sclerosis after a high risk clinically isolated syndrome

AU - Butzkueven, H.

AU - Ponsonby, A-L

AU - Stein, M.

AU - Lucas, R.

AU - Mason, D.

AU - Broadley, S.

AU - Kilpatrick, T.

AU - Lechner-Scott, J.

AU - Barnett, M.

AU - Carroll, W.

AU - Andrew, J.

AU - Campbell, H.

AU - Morahan, J.

AU - Dear, K.

AU - Taylor, B.

PY - 2022/10

Y1 - 2022/10

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000866540803454

M3 - Abstract/Meeting Abstract

SN - 1352-4585

VL - 28

SP - 978

EP - 979

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

IS - 3_SUPPL

T2 - 38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis

Y2 - 26 October 2022 through 28 October 2022

ER -

Results from PREVANZ, a phase 2b placebo controlled double blind dose ranging study of vitamin D to prevent progression to definite multiple sclerosis after a high risk clinically isolated syndrome

Other files and links

Cite this